Rx Post-Approval Duration Of Use Is Not Indicator Of Safety – FDA Editorial
Executive Summary
The postmarketing safety of prescription drugs cannot be predicted using specific time markers following approval, FDA Office of Medical Policy Director Robert Temple, MD, maintained in an editorial in the May 1 Journal of the American Medical Association
You may also be interested in...
Lower Level Of Innovation Could Undermine Expedited Approval Pathways
A Health Affairs study notes that the rate of serious post-marketing safety concerns has risen while PDUFA has pushed down drug review times, feeding into concerns about the increasing use of expedited approvals.
FDA Debates The “Slowdown”: Temple Sees No Sign Of Excess Caution
An analysis of recent drug approvals that took longer than one year shows no indications of a more conservative attitude by FDA, Office of Medical Policy Director Robert Temple, MD, told the Food & Drug Law Institute conference April 17 in Washington, D.C
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011